Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo Reinforces Commitment To Pain With Novel Phase II Drug License

This article was originally published in The Pink Sheet Daily

Executive Summary

Endo licenses axomadol for chronic pain and diabetic neuropathic pain from Grunenthal; sNDA for Valstar in bladder cancer also approved.
Advertisement

Related Content

Endo Plans Valstar Relaunch In Second Half
Endo Plans Valstar Relaunch In Second Half
Endo Branches Out With $370M Indevus Acquisition
Endo Branches Out With $370M Indevus Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS069195

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel